Universal Time: 08:11  |  Local Time: 08:11 (3h GMT)
Select your timezone:

Abstract Session
Kidney - Acute Rejection

Monday September 23, 2024 | 08:00 to 09:15
Room: TBD
Track: N/A


Dr. William R Mulley, Australia
A randomised controlled trial of intravenous immunoglobulin (IVIg) compared with standard of care for the treatment of chronic active antibody mediated rejection (VIPAR)

Mr. Hector Tejeda, Netherlands
Tissue-resident memory T cells in human kidney transplants have alloreactive potential

Dr. Abhishek Vashisth, India
Graft function stabilisation in chronic AMR: Can Tocilizumab be an option

Ms. Shubhi Kamthan, India
Urinary cytokine and microparticles in antibody-mediated renal allograft rejection

Prof. Enver Akalin, United States
Not all transplant glomerulopathy related to chronic antibody-mediated rejection

Dr. Erol Demir, Turkey
Desensitization-Resistant Eplet-Specific HLA Antibodies

Dr. Gillian Divard, France
Mixed rejection phenotype and impact on allograft outcomes after kidney transplantation: multicenter prospective cohort study.

Mr. Liang Wu, Netherlands
Dynamic release of kidney-derived urinary extracellular vesicles: potential biomarkers for acute rejection in kidney transplantation

© 2024 TTS 2024